RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1

Registered title, quoted from ClinicalTrials.gov

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06464861, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and other inert B-cells NHL conversion type:

    Inclusion criterion 2

  3. Refractory or relapsed DLBCL refers to the failure to achieve complete remission after 2-line treatment; disease progression during any treatment, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation ;

    Inclusion criterion 3

    Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative) and anthracyclines;

    Inclusion criterion 6

    Allow patients who have previously received CAR-T cell therapy and have failed or relapsed after 3 months of evaluation;

    Inclusion criterion 20

    Had received gene therapy within the past 3 months;

    Exclusion criterion 4

    Patients who received antitumor therapy earlier but did not recover from the toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia);

    Exclusion criterion 8

  4. ECOG score 0-2 points;

    Inclusion criterion 10

  5. Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min;

    Inclusion criterion 13

    Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;

    Inclusion criterion 14

  6. At least one measurable lesion with the longest diameter ≥ 1.5 cm exists;

    Inclusion criterion 7

  7. Patents infected with hepatitis B (HBsAg positive, but HBV-DNA \< 103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons;

    Exclusion criterion 6

  8. Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial

    Inclusion criterion 21

    Lactating women who are unwilling to stop breastfeeding;

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06464861, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-75 years old, no gender limit;
  • Histologically diagnosed as diffuse large B-cell lymphoma (DLBCL), transforming follicular lymphoma (TFL), primary mediastinal B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and other inert B-cells NHL conversion type:
  • Refractory or relapsed DLBCL refers to the failure to achieve complete remission after 2-line treatment; disease progression during any treatment, or disease stable time equal to or less than 6 months; or disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation ;
  • Refractory or relapsed MCL must be resistant to or intolerable to BTK inhibitors;
  • Refractory or relapsed indolent B-cell NHL is the failure or recurrence of third-line treatment;
  • Previous treatment must include CD20 monoclonal antibody treatment (unless the subject is CD20 negative) and anthracyclines;
  • At least one measurable lesion with the longest diameter ≥ 1.5 cm exists;
  • The expected survival period is ≥12 weeks;
  • The puncture section of the tumor tissue was positive for CD19 expression;
  • ECOG score 0-2 points;
  • Sufficient organ function reserve:
  • Alanine aminotransferase, aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value);
  • Creatinine clearance rate (Cockcroft-Gault method) ≥60 mL/min;
  • Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;
  • Glomerular filtration rate\>50Ml/min
  • Cardiac ejection fraction (EF) ≥50%;
  • Under natural indoor air environment, basic oxygen saturation\>92%
  • Allow a previous stem cell transplantation
  • The approved anti-B-cell lymphoma treatments, such as systemic chemotherapy, systemic radiotherapy, and immunotherapy, have been completed for at least 3 weeks before the study medication;
  • Allow patients who have previously received CAR-T cell therapy and have failed or relapsed after 3 months of evaluation;
  • Female subjects of childbearing age must have a negative pregnancy test and agree to take effective contraceptive measures during the trial
  • Two tests for the new coronavirus or swine flu virus are negative.

Exclusion Criteria:

  • Allergic to any of the components of cell products;
  • History of other tumors;
  • Acute GvHD or extensive chronic GvHD with grade II-IV (Glucksberg standard) in the past or are receiving anti-GVHD treatment;
  • Had received gene therapy within the past 3 months;
  • Active infections requiring treatment (except for simple urinary tract infections, bacterial pharyngitis); however, prophylactic antibiotics, antiviral and antifungal infection treatment are permitted;
  • Patents infected with hepatitis B (HBsAg positive, but HBV-DNA \< 103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons;
  • Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association\'s cardiac function grading criteria;
  • Patients who received antitumor therapy earlier but did not recover from the toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia);
  • Subjects with a history of epilepsy or other central nervous system disorders;
  • Head-enhanced CT or MRI showing evidence of central nervous system lymphoma;
  • Lactating women who are unwilling to stop breastfeeding;
  • Any other factors that the investigator believes may increase the risk to the subject or interfere with the test results.

Quoted from ClinicalTrials.gov, NCT06464861, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06464861, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06464861